# Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting

## TL;DR

Starting evolocumab early in hospital for high-risk heart patients undergoing surgery helps lower cholesterol and reduce cardiovascular events over two years.

## Contribution

Demonstrates early in-hospital evolocumab use improves cholesterol and outcomes in ACS patients undergoing CABG.

## Key findings

- Evolocumab achieved 73.3% LDL-C <55 mg/dL vs 29.3% with standard therapy at 24 months.
- MACE occurred in 10.0% of evolocumab patients vs 24.4% with standard therapy.
- Evolocumab was well tolerated with no discontinuations due to adverse events.

## Abstract

Patients with acute coronary syndrome (ACS) who require coronary artery bypass grafting (CABG) remain at very high ischemic risk due to diffuse native disease and vein graft vulnerability. This study aimed to assess whether very early in-hospital initiation of evolocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitor, on top of statins improves cholesterol control and mid-term cardiovascular outcomes in this high-risk population.

We performed a single-center, retrospective cohort study of 74 ACS patients undergoing isolated CABG (January 2022–July 2023) at Anthea Hospital GVM Care & Research, Bari, Italy. All received high-intensity statin therapy ± ezetimibe (STANDARD, n = 43), while 31 also received evolocumab 140 mg every two weeks (EVOLOCUMAB), initiated pre-angiography, preoperatively, or within 72 h post-CABG. The primary endpoints were LDL cholesterol (LDL-C) trajectory and attainment of <55 mg/dL at 24 months, and major adverse cardiovascular events (MACE: cardiovascular death, spontaneous myocardial infarction, or any revascularization).

Seventy-one patients completed 24-month follow-up (EVOLOCUMAB n = 30; STANDARD n = 41). Baseline LDL-C was similar between groups (∼156 mg/dL). Evolocumab produced rapid and durable LDL-C reduction: at 24 months, mean LDL-C was 52 ± 11 mg/dL (EVOLOCUMAB) vs. 82 ± 18 mg/dL (STANDARD, p < 0.001). LDL-C < 55 mg/dL was achieved by 73.3% of EVOLOCUMAB vs. 29.3% of STANDARD patients (p < 0.001). MACE occurred in 10.0% (EVOLOCUMAB) vs. 24.4% (STANDARD), with lower risk in EVOLOCUMAB (HR 0.48, 95% CI 0.22–0.94; p = 0.035), mainly due to fewer repeat revascularizations. Evolocumab was well tolerated; no discontinuations due to adverse events were observed

In ACS patients undergoing CABG, very-early in-hospital evolocumab plus statins achieved sustained LDL-C lowering and fewer adverse cardiovascular events over two years. Given the retrospective observational design, causal inference is limited and residual confounding cannot be excluded. These findings are hypothesis-generating and require confirmation in randomized trials.